By 2030, the global liver disease treatment market is forecasted to achieve $36.45 billion, expanding at a CAGR of 5.7%.
PORTLAND, IN, UNITED STATES, August 20, 2025 /EINPresswire.com/ -- As per the report, the global liver disease treatment market generated $20.67 billion in 2020, and is projected to garner $36.45 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030.
The growth of the global liver disease treatment market is attributed to increase in prevalence of liver diseases, rise in drug discovery and research, development activities for safe and effective therapies. Moreover, increase in alcohol consumption, obesity and rise in healthcare expenditure is expected to drive the market growth during the forecast years
Drivers, restraints, and opportunities
Increase in incidence of liver diseases, surge in government and non-government awareness program, and surge in geriatric population coupled with rise in alcohol consumption and poor dietary habits have boosted the growth of the global liver disease treatment market. However, strict regulatory approvals related to liver diseases treatment drugs and vaccines and resistance to antiviral drugs used in treatment of hepatitis B and C hamper the market growth. On the contrary, presence of strong pipeline products is expected to open new opportunities for the market players in the future.
Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/388
Liver Disease Treatment Market Segmentation
Liver is one of the most important organs in the human body, since it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase “liver disease” refers to a wide range of issues that cause the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases.
The antiviral drugs segment held the lion’s share
By treatment type, the antiviral drugs segment dominated the market in 2020, accounting for more than two-fifths of the global liver disease treatment market, due to rise in prevalence of virus infected liver diseases and availability of branded and generic drugs. However, the immunosuppressants segment is projected to register the highest CAGR of 7.5% during the forecast period, owing to rise in autoimmune diseases and increase in liver transplants.
Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/388
The cancer segment to portray the highest CAGR through 2030
By end user, the cancer segment is expected to showcase the highest CAGR of 7.8% during the forecast period, due to rise in alcohol consumption, obesity, and hepatitis cases. However, the hepatitis segment held the lion’s share in 2020, contributing to more than four-fifths of the global liver disease treatment market, owing to rise in the number of hepatitis cases across the globe.
North America held the largest share
By region, the market across North America held the largest share in 2020, accounting for more than two-fifths of the market, due to rise in geriatric population, adoption of advanced technologies, robust R&D infrastructure for life science researchers, and improved liver disease treatment. However, the global liver disease treatment market across Asia-Pacific is expected to manifest the highest CAGR of 7.8% during the forecast period, owing to rise in liver diseases, increase in public-private investments, and government support for pharmaceutical and biotechnology R&D.
Major market players:
AbbVie Inc.
Astellas Pharma Inc.
Abbott Laboratories
Eli Lilly and Company
Bristol Myers Squibb
Emergent BioSolutions (Cangene bioPharma)
F. Hoffman-LA Roche
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Gilead Sciences, Inc.
Viatris Inc.
Read More:
generic drugs market https://www.alliedmarketresearch.com/generic-drugs-market
stem cell umbilical cord blood market https://www.alliedmarketresearch.com/stem-cell-umbilical-cord-blood-ucb-market
sleep apnea implants market https://www.alliedmarketresearch.com/sleep-apnea-implants-market-A11550
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
The growth of the global liver disease treatment market is attributed to increase in prevalence of liver diseases, rise in drug discovery and research, development activities for safe and effective therapies. Moreover, increase in alcohol consumption, obesity and rise in healthcare expenditure is expected to drive the market growth during the forecast years
Drivers, restraints, and opportunities
Increase in incidence of liver diseases, surge in government and non-government awareness program, and surge in geriatric population coupled with rise in alcohol consumption and poor dietary habits have boosted the growth of the global liver disease treatment market. However, strict regulatory approvals related to liver diseases treatment drugs and vaccines and resistance to antiviral drugs used in treatment of hepatitis B and C hamper the market growth. On the contrary, presence of strong pipeline products is expected to open new opportunities for the market players in the future.
Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/388
Liver Disease Treatment Market Segmentation
Liver is one of the most important organs in the human body, since it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase “liver disease” refers to a wide range of issues that cause the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases.
The antiviral drugs segment held the lion’s share
By treatment type, the antiviral drugs segment dominated the market in 2020, accounting for more than two-fifths of the global liver disease treatment market, due to rise in prevalence of virus infected liver diseases and availability of branded and generic drugs. However, the immunosuppressants segment is projected to register the highest CAGR of 7.5% during the forecast period, owing to rise in autoimmune diseases and increase in liver transplants.
Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/388
The cancer segment to portray the highest CAGR through 2030
By end user, the cancer segment is expected to showcase the highest CAGR of 7.8% during the forecast period, due to rise in alcohol consumption, obesity, and hepatitis cases. However, the hepatitis segment held the lion’s share in 2020, contributing to more than four-fifths of the global liver disease treatment market, owing to rise in the number of hepatitis cases across the globe.
North America held the largest share
By region, the market across North America held the largest share in 2020, accounting for more than two-fifths of the market, due to rise in geriatric population, adoption of advanced technologies, robust R&D infrastructure for life science researchers, and improved liver disease treatment. However, the global liver disease treatment market across Asia-Pacific is expected to manifest the highest CAGR of 7.8% during the forecast period, owing to rise in liver diseases, increase in public-private investments, and government support for pharmaceutical and biotechnology R&D.
Major market players:
AbbVie Inc.
Astellas Pharma Inc.
Abbott Laboratories
Eli Lilly and Company
Bristol Myers Squibb
Emergent BioSolutions (Cangene bioPharma)
F. Hoffman-LA Roche
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Gilead Sciences, Inc.
Viatris Inc.
Read More:
generic drugs market https://www.alliedmarketresearch.com/generic-drugs-market
stem cell umbilical cord blood market https://www.alliedmarketresearch.com/stem-cell-umbilical-cord-blood-ucb-market
sleep apnea implants market https://www.alliedmarketresearch.com/sleep-apnea-implants-market-A11550
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.